Category: Top 10
-
Pharma giants post strong half-year 2025 results
J&J, Roche, Merck, AbbVie, Pfizer, AstraZeneca, and Novartis report Q2 2025 results, find out the top earners, and YOY analysis.
-
Top 10 highest grossing drugs in 2024: Keytruda dominance continues
The Drug and Device World counts down the highest-grossing drugs of the last year, with Merck & Co.’s Keytuda being the clear winner, generating just under $30bn in sales.
Latest posts
-
ASH25: Gallop’s LYT-200 shows unprecedented survival in AML
The company’s execs talk about the striking efficacy and safety signals seen in Phase I data, the science behind the molecule, and their vision for transforming AML therapy.
-
Urologic Health secures $11 million for non-invasive bladder monitoring
Urologic Health raises $11million seed funding to advance a catheter-free bladder monitoring platform toward FDA clearance and US market entry.
-
Novo Nordisk’s denecimig cuts bleeding in hemophilia A regardless of inhibitors
Phase III trial shows once‑monthly and once‑weekly denecimig (Mim8) significantly reduces annualized bleeding rate versus standard care, with up to 95% of patients bleed‑free.
-
Beyond the Snapshot: Continuous physiologic monitoring in clinical trials
Vivalink’s CEO discusses how continuous physiologic monitoring is transitioning from a niche tool for early-stage feasibility studies to a core component of late-stage drug development.